TR199902980T2 - Diabetin tedavisi i�in leptin antagonistlerinin kullan�m�. - Google Patents

Diabetin tedavisi i�in leptin antagonistlerinin kullan�m�.

Info

Publication number
TR199902980T2
TR199902980T2 TR1999/02980T TR9902980T TR199902980T2 TR 199902980 T2 TR199902980 T2 TR 199902980T2 TR 1999/02980 T TR1999/02980 T TR 1999/02980T TR 9902980 T TR9902980 T TR 9902980T TR 199902980 T2 TR199902980 T2 TR 199902980T2
Authority
TR
Turkey
Prior art keywords
treatment
diabetes
leptin antagonists
leptin
antagonists
Prior art date
Application number
TR1999/02980T
Other languages
English (en)
Turkish (tr)
Inventor
Cawthorne Michael
Emilsson Valur
Liu Yong-Ling
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of TR199902980T2 publication Critical patent/TR199902980T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TR1999/02980T 1997-06-06 1997-06-06 Diabetin tedavisi i�in leptin antagonistlerinin kullan�m�. TR199902980T2 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1997/002240 WO1998055139A1 (en) 1997-06-06 1997-06-06 Use of leptin antagonists for the treatment of diabetes

Publications (1)

Publication Number Publication Date
TR199902980T2 true TR199902980T2 (xx) 2000-05-22

Family

ID=8166613

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02980T TR199902980T2 (xx) 1997-06-06 1997-06-06 Diabetin tedavisi i�in leptin antagonistlerinin kullan�m�.

Country Status (9)

Country Link
EP (1) EP0986397A1 (ja)
JP (1) JP2002504102A (ja)
KR (1) KR20010013414A (ja)
AU (1) AU2951797A (ja)
CA (1) CA2293504A1 (ja)
HU (1) HUP0003428A3 (ja)
IL (1) IL133136A0 (ja)
TR (1) TR199902980T2 (ja)
WO (1) WO1998055139A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
WO2005077072A2 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
AU2006213607A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
US20120071401A1 (en) 2009-04-10 2012-03-22 Amylin Pharamaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
EP2621519B1 (en) 2010-09-28 2017-06-28 Aegerion Pharmaceuticals, Inc. Leptin-abd fusion polypeptides with enhanced duration of action
JP6040464B2 (ja) 2011-07-08 2016-12-07 アエゲリオン・ファーマシューティカルズ・インコーポレイテッドＡｅｇｅｒｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
DK2900230T3 (en) 2012-09-27 2018-11-12 Childrens Medical Ct Corp RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF
SI3074033T1 (sl) 2013-11-26 2019-03-29 The Children's Medical Center Corporation Spojine za zdravljenje debelosti in postopki njihove uporabe
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
RS64850B1 (sr) 2016-09-12 2023-12-29 Amryt Pharmaceuticals Inc Metodi za detektovanje neutrališućih antitela na leptin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
EP0836479A2 (en) * 1995-06-30 1998-04-22 Eli Lilly And Company Methods for treating diabetes

Also Published As

Publication number Publication date
CA2293504A1 (en) 1998-12-10
HUP0003428A3 (en) 2001-12-28
IL133136A0 (en) 2001-03-19
JP2002504102A (ja) 2002-02-05
EP0986397A1 (en) 2000-03-22
WO1998055139A1 (en) 1998-12-10
KR20010013414A (ko) 2001-02-26
AU2951797A (en) 1998-12-21
HUP0003428A2 (hu) 2001-05-28

Similar Documents

Publication Publication Date Title
TR199902980T2 (xx) Diabetin tedavisi i�in leptin antagonistlerinin kullan�m�.
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
DE60044041D1 (de) Exendine zur Glucagon Suppression
ATE172971T1 (de) Heterocyclische neurokinin-antagonisten
IS2759B (is) CGRP-viðtakamótlyf, lyfjaefnablanda og notkun á efnablöndunum til framleiðslu á lyfi
NO20053224D0 (no) Patient controlled drug administration device.
ZA200502247B (en) Selected CGRP antagonists, method for production and use thereof as medicament.
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
ID21861A (id) Penggunaan antagonis leptin untuk pengobatan daya tahan terhadap insulin dalam diabetes tipe ii
RS20060066A (en) Use of angiotensin ii receptor antagonists, especially telmisartan, in order to increase insulin sensitivity
DE60105922D1 (de) Tragbares, autarkes Medikamenteninfusionsgerät
DE60008374D1 (de) Anästhetische zubereitung enthaltend einen nmda-antagonisten und einen alpha-2 adrenergen agonisten
CY1105211T1 (el) Φαρμακευτικοι συνδυασμοι που πepιλαμβανουν εναν ανταγωνιστη του υποδοχεα p2τ και μελαγατρανη
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
PT1500654E (pt) Derivados de benzoxazinona, sua preparacao e utilizacao como medicamentos
DE69814394D1 (de) Verwendung von levobupivacain
NZ337827A (en) Use of GluR5 receptor antagonists in the manufacture of medicaments for treating pain
ATE399010T1 (de) Kombination enthaltend einen at1-rezeptor antagonisten und einen insulinsekretion verstärker oder einen insulin sensibilisator
ID23799A (id) Penggunaan antagonis reseptor 5ht2 spesifik untuk pembuatan obat obatan yang berguna dalam pengobatan sindrom apnea saat tidur
DK0981347T3 (da) Anvendelsen af levobupivacain i ansigtkirurgi
IL184121A0 (en) Urotensin-ii agonists polypeptide and its use for manufacture of medicaments
BR0109342B1 (pt) agulha médica usada como uma agulha dental ou de insulina.
AR031122A1 (es) Uso de antagonistas de endotelina en la fabricacion de medicamentos utiles para el tratamiento del cancer y el dolor asociado con el mismo
NO995940L (no) Anvendelse av leptin antagonister for behandling av diabetes
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde